RecruitingPHASE2, PHASE3NCT05327114
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Studying Chronic inflammatory demyelinating polyneuropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Janssen Research & Development, LLC
- Principal Investigator
- Janssen Research & Development, LLC Clinical TrialJanssen Research & Development, LLC
- Intervention
- Nipocalimab(drug)
- Enrollment
- 201 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2028
Study locations (30)
- IMMUNOe Health and Research Centers, Centennial, Colorado, United States
- Healthcare Innovations Institute Inc, Coral Springs, Florida, United States
- Neurology Associates PA, Maitland, Florida, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- Boston Clinical Trials, Boston, Massachusetts, United States
- Beaumont Hospital Royal Oak, Royal Oak, Michigan, United States
- The Neurological Institute of New York, New York, New York, United States
- South Shore Neurologic Associates - Patchogue, Patchogue, New York, United States
- The Neurological Institute, PA, Charlotte, North Carolina, United States
- Cleveland Clinic Main Campus, Cleveland, Ohio, United States
- Austin Neuromuscular Center, Austin, Texas, United States
- Advocate Health - Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States
- Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
- Hospital Gral Agudos Ignacio Pirovano, Buenos Aires, Argentina
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05327114 on ClinicalTrials.govOther trials for Chronic inflammatory demyelinating polyneuropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07540221A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating PolyradiculoneuropathyGrifols Therapeutics LLC
- RECRUITINGPHASE3NCT06752356A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Kedrion S.p.A.
- RECRUITINGNCT07273903Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart DevicesHeinrich-Heine University, Duesseldorf
- RECRUITINGPHASE3NCT07091630A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDPargenx
- ENROLLING BY INVITATIONPHASE2NCT07188844An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Immunovant Sciences GmbH
- RECRUITINGNCT07154524Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)University of Ulm
- RECRUITINGPHASE3NCT06920004A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPargenx
- RECRUITINGNCT07264426Real-World Efgartigimod Effectiveness in CIDP: A Prospective Studyargenx
See all trials for Chronic inflammatory demyelinating polyneuropathy →